Business Context and Reporting Period
This Form 8-K Current Report was filed by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp) on May 3, 2019, with the report date finalized on May 6, 2019. The filing discloses the appointment of a new executive officer and significant business developments regarding the company's EksoGT exoskeleton product.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and operational milestones.
- Executive Compensation (New CCO): Annual base salary of $275,000.
- Target Bonus: $225,000 (pro-rated for 2019).
- Equity Grant: Option to purchase 480,000 shares of common stock, vesting over four years (25% on first anniversary, remainder monthly).
- Severance: 6 months' salary if terminated without cause before the first anniversary; 9 months' salary if terminated after.
Material Changes and Operational Updates
The filing details two primary material events:
- Executive Appointment: William (Bill) Shaw was appointed Chief Commercial Officer, effective May 6, 2019. He brings over 15 years of medical device sales experience, most recently from Zimmer Biomet Robotics.
- Product Expansion:
- Kindred Hospital: Expanded a pilot program for the EksoGT exoskeleton to over 20 freestanding in-patient rehabilitation hospitals in 13 states.
- Singapore Clinical Study: National University Health System in Singapore adopted three EksoGT units for a clinical study focusing on stroke and spinal cord injuries in the elderly.
Guidance, Risks, and Contingencies
The filing contains no forward-looking financial guidance or specific risk factors beyond standard employment contingencies.
- Change of Control: In the event of a change of control followed by termination without cause within one year, Mr. Shaw is entitled to 9 months' salary, a pro-rated bonus, COBRA benefits, and acceleration of all unvested options.
- Performance Conditions: Bonus payments are contingent on performance against company milestones.
Key Facts for Investor Verification
- Verify the actual start date and integration progress of the new Chief Commercial Officer, William Shaw.
- Confirm the commercial revenue impact of the expanded Kindred Hospital pilot program across 20+ sites.
- Monitor the timeline and results of the clinical study with the National University Health System in Singapore.
- Review the vesting schedule and exercise price of the 480,000 stock options granted to Mr. Shaw.